Lexeo Therapeutics, Inc. (LXEO) Misses Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Lexeo Therapeutics (LXEO) PT Lowered to $18 at Leerink Partners, 'we continue to see favorable risk/reward into 2H25'
March 24, 2025 10:20 AM EDTLeerink Partners analyst Mani Foroohar lowered the price target on Lexeo Therapeutics (NASDAQ: LXEO) to $18.00 (from $19.00) while maintaining a Outperform rating.
The analyst comments "Todays update is an incremental positive for both clinical programs. PKP2 showed an early clinical signal... More
